Efficiency Of CIK Adoptive Cells In The Treatment Of Triple Negative Breast Cancer

Objective To evaluate the survival of triple-negative breast cancer(TNBC)treated by cytokine-induced killer(CIK)cells in recent years,patients who received conventional chemotherapy combined with CIK adoptive immunotherapy and conventional chemotherapy alone were followed-up.In this study,we observed that whether there is a difference in the efficiency of conventional chemotherapy combined with CIK adoptive cell therapy compared with chemotherapy alone.Methods Totally 340 cases of patients with triple-negative breast cancer between January 1,2010 and June 30,2014 were recruited from Tianjin Medical University Cancer Institute and Hospital.All patients met the inclusion criteria of this study:77 patients received CIK cell immunotherapy following regular chemotherapy(combined group);263 patients received regular chemotherapy alone(chemotherapy group).The primary endpoint was overall survival(OS)and disease-free survival(DFS),and the treatment response and adverse events were also evaluated.At the same time,the disease control rate of the two groups of patients were evaluated.In this study,the following-up of patients was going on by phone.All calculations were performed using the SPSS 18.0 software,and a difference with a P value of less than 0.05 was considered significant.Results The 1-,2-,3-,4-,and 5-year OS rates of patients with CIK cell therapy combined with chemotherapy were 96.0%,94.3%,94.3%,94.3%,and 94.3%,respectively.The 1-,2-,3-,4-,and 5-year OS rates of patients with chemotherapy alone were 95.4%,90.9%,88.6%,88.2%and 85.6%,respectively.It indicates that the CIK cells therapy can significantly improve the OS rates of TNBC patients(p=0.035).The 1-,2-,3-,4-,and 5-year DFS rates of patients treated with CIK cells therapy combined with chemotherapy were 94.8%,87.0%,80.5%,80.5%,and 77.9%,respectively.And the DFS rates of patients with chemotherapy alone were 90.9%,82.1%,76.0%,71.2%and 69.8%,respectively.DFS rates in the CIK cells therapy group were higher than that in the chemotherapy alone group,however,there was no significantly difference between the two groups(p=0.159).Multivariate analysis showed that the DFS in the combined group with a Kappa score of ?90 and clinical stage ?/?A was longer,but a Kappa score of ?90 and clinical stage?/?A had no significant effect in OS.None of the 77 patients who received CIK cell reinfusion developed treatment-related fever,there was 6 patients developed mild liver dysfunction,and the liver function returned to normal after symptomatic treatment.Conclusions The data suggested that CIK cell immunotherapy improved the efficiency of regular chemotherapy in TNBC patients,and the side effects of CIK cell immunotherapy were mild.